Osteoporosis Drugs Market Size, Share, Industry, Forecast and outlook (2023-2030)

Global Osteoporosis Drugs Market is Segmented By Drug Class (Bisphosphonates, RANK Ligand Inhibitors, Selective Estrogen Receptor Modulators, Parathyroid Hormone Analog, Strontium, Calcitonin, Anti-Sclerostin, and Cathepsin K Inhibitor) By Product Type (Branded and Generics), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Other), and By Region (North America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030

Osteoporosis Drugs Market Overview

The Global Osteoporosis Drugs Market reached US$ 14,066.4 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 19,336.6 million by 2030. The global osteoporosis drugs market is expected to exhibit a CAGR of 4.1% during the forecast period (2023-2030). The rising incidence of osteoporosis or arthritis, the expansion of the therapeutic pipeline, investments by biotechnology and pharmaceutical companies in resaerch and development, and the launch of more advanced and novel products are all contributing factors to the growth of the global market for osteoporosis drugs.  

The osteoporosis drugs market scope includes drug class of osteoporosis drugs such as selective estrogen receptor modulators, bisphosphonates, RANK ligand inhibitors, parathyroid hormone analog, strontium, calcitonin, anti-sclerostin and others leading to a surge in osteoporosis drugs market share. Furthermore, the novel therapies significantly increasing and is being highly researched by researchers. 

Osteoporosis Drugs Market Scope

To Know more Insights - Download Sample

Osteoporosis Drugs Market Dynamics

The Growing Investments in Research and Development by Biotechnology and Pharmaceutical Companies Drive the Growth of the Osteoporosis Drugs Market

The global osteoporosis drugs market is expanding owing to the the increasing research studies for osteoporosis drugs, rising regulatory approvals for novel products, rising geriatric population, new novel technologically advanced therapies. 

In the coming years, the market will rise as a result of rising biotechnology and pharmaceutical companies' spending in R&D. For instance, in October 2020, the Italian pharmaceutical regulatory body approved human clinical studies for the osteoporosis medicine raloxifene. Researchers believe this treatment may also help people with COVID-19 feel better and be less contagious. Positive clinical trial outcomes may therefore result in new therapeutic alternatives, which would spur market expansion in the future.

Furthermore, another important driver of the market's expansion is the growing osteoporosis incidence around the world among people, who are more likely to have reduced bone density. According to Osteoporosis Canada 2022, More than 2.3 million Canadians suffer from osteoporosis. Among such, osteoporosis is to blame for 80% of fractures in adults 50 and older. 

Growing Clinical Trials and Rising Geriatric Population Creates Lucrative Opportunities  for Manufacturers

There is a growing market opportunity owing to growing expenditure on research and development proficiencies by key players for novel technological advancements. The rising prevalence of osteoporosis is also a market trend driving the market. 

For instance, according to World Health Organization 2022, one in six individuals on the planet will be 60 or older by 2030. By this point, there will be 1.4 billion people over the age of 60, up from 1 billion in 2020. The number of individuals in the world who are 60 or older will double (to 2.1 billion) by 2050. Between 2020 and 2050, the number of people 80 or older is projected to treble, reaching 426 million.

A Low Rate of Treatment with Bone-Directed Medications will Hamper the Growth of the Market

However, a recent review of a sizable countrywide private insurance database revealed that treatment rates for osteoporosis, or bone loss, medications substantially decreased over the past decade from 15% to 8%. 

According to a study whose findings were provided at ENDO 2021, the Endocrine Society's annual meeting, less than one in ten economically insured patients across the United States who broke a hip, one of the most serious complications of osteoporosis, received any osteoporosis medical treatment throughout two calendar quarters of their fracture. These elements limit market expansion during the anticipated term.

Oesophageal cancer incidence has been statistically linked to bisphosphonates, but it is unclear whether this is a real treatment impact or more likely the result of confounding variables in the osteoporosis group.

Osteoporosis Drugs Market Segment Analysis

The global osteoporosis drugs market is segmented based on drug class, product type, distribution channel and region.

Owing to the High Research, the RANK Ligand Inhibitors Drug Class Segment Accounted for Approximately 31.7% of the Osteoporosis Drugs Market Share in 2022.

Patients who are at a high risk for bone fractures are treated for osteoporosis using RANK ligand (RANKL) inhibitors. Positive patient findings connected to rank ligand inhibitors result in the great development potential realized. The considerable advancements in bone metabolism are to blame for the favorable patient outcomes.

Additionally, rank ligand inhibitors can be combined with other medications to enhance the effectiveness of the entire treatment plan. The aforementioned factor is also considered to be among the essential elements responsible for generating lucrative prospects. Reduced cell bone turnover and enhanced bone mineral density are additional benefits of rank ligand inhibitors, which suggests strong demand. 

Source: DataM Intelligence Analysis (2023)

Osteoporosis Drugs Market Geographical Penetration

North America Accounted for Approximately 38.3% of the Market Share in 2022, Owing to the Strong Presence of Major Players and Increasing Healthcare Infrastructure Investment

Due to the rising need for osteoporosis drugs for treatment purpose in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for osteoporosis drugs. 

Increasing expenditure on healthcare and rising awareness among people, advancement of technologies for treatment, and increase in pharmaceutical establishment across the region are also contributing to the market growth in this region. Rising novel technology launches to support osteoporosis drugs for prevention of bone loss and increasing bone density also drives the market growth.   

Source: DataM Intelligence Analysis (2023)

Osteoporosis Drugs Market Players

The major global players in the osteoporosis drugs market include F. Hoffmann-La Roche, Novartis AG, Merck & Co, Pfizer, Eli Lilly and Co. (Lilly), Amgen Inc., Radius Health, Teva Pharmaceutical Industries, GSK and AbbVie among others. 

COVID-19 Impact on Osteoporosis Drugs Market

Russia Ukraine Conflict Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global osteoporosis drugs market, owing to the medium prevalence and absence of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global osteoporosis drugs market growth over the forecast period.

By Drug Class

• Bisphosphonates
• RANK Ligand Inhibitors
• Selective Estrogen Receptor Modulators
• Parathyroid Hormone Analog
• Strontium
• Calcitonin
• Anti-Sclerostin 
• Others

By Product Type

• Branded
• Generics

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • The U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
• Middle East and Africa

Key Developments

• In May 2023, inspiring phase I clinical data of TST002 (Blosozumab) in Chinese patients with low bone mineral density (BMD) have been reported by a clinical-stage biopharmaceutical company with fully integrated capabilities in discovery, research, development, and manufacturing of antibody-based therapeutics, Transcenta Holding Limited. Following a single intravenous injection at different doses, TST002 (Blosozumab) substantially raised BMD at day 85 while being well tolerated.
• In May 2023, Prolia (denosumab) injection decreased fracture risk in patients against oral alendronate, a commonly recommended bisphosphonate medication, according to new findings from a real-world research of nearly half a million postmenopausal women having osteoporosis in the U.S. medicare program. Over time, taking Prolia was also linked to significant decreases in the risk of fracture.
• In December 2022, the FDA authorized a parathyroid hormone-related peptide [PTHrP(1-34)] analog, TYMLOS (abaloparatide), for treating or improving bone density in men with osteoporosis who are at high risk of fracture (defined as having a previous instance of osteoporotic fracture or several risk factors), or in those who have not responded or are intolerant of any other available osteoporosis therapy. 

Why Purchase the Report?

• To visualize the global osteoporosis drugs market segmentation based on drug class, product type, distribution channel and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of osteoporosis drugs market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global osteoporosis drugs market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

For more Pharmaceutical related reports, please click here